NSCLC Clinical Trials in Omaha, Nebraska

3 studies are recruiting for nsclc in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    University of Nebraska Medical Center Buffet Cancer Center, Omaha, Nebraska
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  2. Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

    A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha, Nebraska
    Locations
    8 in total
    Run by
    Orano Med Theranostics, SAS

    See if you can join NCT05283330 on ClinicalTrials.gov

  3. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

    TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Nebraska Cancer Specialists, Omaha, Nebraska
    Locations
    18 in total
    Run by
    Tango Therapeutics, Inc.

    See if you can join NCT06922591 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.